John Goldberg
Chief Tech/Sci/R&D Officer bij RAFAEL HOLDINGS, INC.
Vermogen: 344 $ op 31-12-2023
Actieve functies van John Goldberg
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 20-11-2023 | - |
Loopbaan van John Goldberg
Eerdere bekende functies van John Goldberg
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 22-02-2022 | 30-06-2023 |
| Corporate Officer/Principal | 01-10-2018 | 22-02-2022 | |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - | - |
Opleiding van John Goldberg
| The University of Chicago | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Beurs
- Insiders
- John Goldberg
- Ervaring
